Get the Stockscreener App
9.375
0.04%
0.035
Adma Biologics Inc stock is traded at $9.375, with a volume of 202.29K.
It is up +0.04% in the last 24 hours and up +6.13% over the past month.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
See More
Previous Close:
$9.41
Open:
$9.47
24h Volume:
202.29K
Relative Volume:
0.06
Market Cap:
$2.10B
Revenue:
$509.86M
Net Income/Loss:
$165.35M
P/E Ratio:
13.83
EPS:
0.6779
Net Cash Flow:
$107.55M
1W Performance:
-4.91%
1M Performance:
+6.13%
6M Performance:
-41.49%
1Y Performance:
-44.53%
1-Day Range:
$9.33
$9.49
1-Week Range:
$9.24
$10.05
52-Week Range:
$7.2101
$20.46
Adma Biologics Inc Stock (ADMA) Company Profile
Name
Adma Biologics Inc
Sector
Industry
Phone
(201) 478-5552
Address
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
9.365 | 2.19B | 509.86M | 165.35M | 107.55M | 0.6779 |
VRTX
Vertex Pharmaceuticals Inc
|
504.50 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
797.12 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
839.28 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
200.51 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
345.17 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Mar-26-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-19-23 | Resumed | Raymond James | Strong Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Nov-11-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-09-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-04-19 | Initiated | Jefferies | Buy |
| Apr-15-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-19 | Resumed | H.C. Wainwright | Buy |
| Dec-11-17 | Reiterated | Maxim Group | Buy |
| Nov-14-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-17 | Upgrade | Maxim Group | Hold → Buy |
| Aug-01-16 | Downgrade | Maxim Group | Buy → Hold |
| Jul-25-16 | Reiterated | Maxim Group | Buy |
| May-13-15 | Reiterated | Maxim Group | Buy |
| Dec-08-14 | Initiated | Oppenheimer | Outperform |
| Dec-01-14 | Reiterated | Maxim Group | Buy |
View All
Adma Biologics Inc Stock (ADMA) Latest News
STATE STREET CORP Buys ADMA Biologics Inc (ADMA) -- Shares Look 49% Undervalued on GF Value - GuruFocus
Can Asceniv Help ADMA Stock Combat IG Market Challenges? - Yahoo
ADMA Biologics Inc (ADMA) Stock Forecasts - Yahoo Finance
ADMA Biologics: The Earnings Reset Still Leaves More Upside (NASDAQ:ADMA) - Seeking Alpha
ADMA Tumbles On Slashed Outlook As Short-Seller Aftermath Meets Competitive Headwinds - Stocktwits
Royal Bank of Canada Buys 759,984 Shares of ADMA Biologics Inc $ADMA - MarketBeat
Janus Henderson Group PLC Trims Stock Holdings in ADMA Biologics Inc $ADMA - MarketBeat
ADMA DEADLINEFINAL REMINDER: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of ADMA Biologics, Inc. to Contact the Firm Today! - ACCESS Newswire
ADMA Biologics, Inc. Deadline: ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, - globenewswire.com
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law - Business Wire
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026 - Eagle-Tribune
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action LawsuitContact Reed Kathrein at Hagens Berman Sobol Shapiro LLP By Application Deadline - PR Newswire
ADMA Biologics Inc (ADMA): Investor Outlook Highlights 71.72% Potential Upside - DirectorsTalk Interviews
Robbins LLP Reminds ADMA Investors of the August 10, 2026 Lead Plaintiff Deadline; Contact the Firm for Information About Recovering Your Losses - PR Newswire
ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
DEADLINE NEXT WEEK: Hagens Berman Advises ADMA Biologics, Inc. Investors to Contact the Firm Before August 10, 2026 - PR Newswire
BTU IMPORTANT DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Peabody Energy Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – BTU - GlobeNewswire Inc.
ADMA DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts ADMA Biologics, Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire
ADMA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ADMA Biolog - The National Law Review
ADMA Biologics 48 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ADMA Biologics, Inc.ADMA - ACCESS Newswire
ADMA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026 - accessnewswire.com
ADMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ADMA Biologics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ADMA Biologics 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ADMA Biologics, Inc.ADMA - Business Wire
ADMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
ADMA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ADMA Biologi - The National Law Review
ADMA BIOLOGICS CLASS ACTION DEADLINE AUGUST 10th: Bragar - GlobeNewswire
MONDAY INVESTOR DEADLINE: ADMA Biologics, Inc. (NASDAQ: ADMA) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
ADMA Shareholder Alert: August 10, 2026 Lead Plaintiff Deadline in ADMA Biologics, Inc. ... - Caledonian Record
ADMA Biologics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
ADMA Shareholder Alert: August 10, 2026 Lead Plaintiff - GlobeNewswire
MONDAY DEADLINE: Berger Montague Advises ADMA Biologics, Inc. (ADMA) Investors to Inquire About a Securities Fraud Class Action by August 10, 2026 - marketscreener.com
State Street (NASDAQ: ADMA) discloses 7.4% ADMA Biologics stake via SSGA advisers - Stock Titan
ADMA Biologics (ADMA) Receives a Buy from Canaccord Genuity - The Globe and Mail
$ADMA Court News: ADMA Biologics Securities Fraud Class - GlobeNewswire
First Trust Advisors LP Raises Stock Holdings in ADMA Biologics Inc $ADMA - MarketBeat
ADMA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ADMA Biologics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - accessnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming DeadlinesADMA - PR Newswire
ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ADMA Biologics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ADMA BIOLOGICS DEADLINE: ROSEN, THE FIRST FILING FIRM, - globenewswire.com
ADMA Biologics (NASDAQ:ADMA) Downgraded to "Strong Sell" Rating by Zacks Research - MarketBeat
ADMA Q2 Earnings Meet, Revenues Miss on Bivigam Weakness - The Globe and Mail
MONDAY INVESTOR DEADLINE: ADMA Biologics, Inc. Investors - GlobeNewswire
Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders - GlobeNewswire
ADMA Biologics (ADMA) Is Up 6.3% After Faster Net Income Growth Than Sales In Q2 2026 - simplywall.st
ADMA Biologics, Inc. Deadline: ADMA Investors with Losses in Excess of $100K Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm - Sahm
ADMA Biologics Inc (ADMA) (Q2 2026) Earnings Call Highlights: As - GuruFocus
ADMA Biologics Inc (ADMA) (Q2 2026) Earnings Call Highlights: Ascentiv Surges 24% as Gross ... - Yahoo Finance
Earnings call transcript: ADMA Biologics posts strong margins in Q2 2026 - Investing.com
Is ADMA Biologics Inc (ADMA) Undervalued After Q2 Earnings Miss? - GuruFocus
ADMA Biologics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Adma Biologics Inc Stock (ADMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adma Biologics Inc Stock (ADMA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grossman Jerrold B | Director |
May 12 '26 |
Buy |
8.01 |
12,500 |
100,125 |
513,884 |
| Grossman Jerrold B | Director |
May 11 '26 |
Buy |
8.01 |
12,500 |
100,125 |
501,384 |
| Guiheen Lawrence P. | Director |
Mar 13 '26 |
Option Exercise |
3.66 |
30,000 |
109,800 |
135,520 |
| Grossman Adam S | President and CEO |
Mar 16 '26 |
Option Exercise |
5.40 |
15,000 |
81,000 |
2,133,777 |
| Grossman Adam S | President and CEO |
Mar 16 '26 |
Sale |
15.16 |
21,000 |
318,360 |
2,112,777 |
0.90%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):